A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Completed · Phase 3 · NCT06109311

Conditions: Type 2 Diabetes

Research payments reported, 2025: $1.5M
U.S. investigators named: 37
Sites paid: 28
Planned or actual enrollment: 546

About the trial

Sponsor: Eli Lilly and Company
Tested: Orforglipron (drug), Placebo (drug)
Dates: Started 2023-11-10; completion 2025-09-15
Results posted: Yes

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.

From ClinicalTrials.gov, last updated 2026-10-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly Export S.a. Puerto Rico Branch reported $1.5M in research payments for this study in 2025 (65 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it